Kura Oncology (NASDAQ:KURA) Insider Sells $397,680.81 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Teresa Brophy Bair sold 31,487 shares of Kura Oncology stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total value of $397,680.81. Following the completion of the sale, the insider owned 195,444 shares in the company, valued at $2,468,457.72. This represents a 13.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Kura Oncology Stock Performance

NASDAQ KURA opened at $11.89 on Monday. The stock has a market cap of $1.06 billion, a PE ratio of -3.53 and a beta of 0.38. The company has a current ratio of 4.73, a quick ratio of 4.71 and a debt-to-equity ratio of 0.12. Kura Oncology, Inc. has a twelve month low of $7.36 and a twelve month high of $12.90. The stock has a fifty day simple moving average of $10.53 and a 200-day simple moving average of $9.47.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11. The firm had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. Equities analysts anticipate that Kura Oncology, Inc. will post -3.23 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KURA. IFP Advisors Inc grew its stake in Kura Oncology by 115.3% during the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after purchasing an additional 1,284 shares in the last quarter. Royal Bank of Canada raised its position in Kura Oncology by 7.6% in the 4th quarter. Royal Bank of Canada now owns 19,577 shares of the company’s stock valued at $203,000 after purchasing an additional 1,375 shares in the last quarter. Allworth Financial LP raised its position in Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after purchasing an additional 1,553 shares in the last quarter. Focus Partners Advisor Solutions LLC raised its position in Kura Oncology by 7.9% in the 4th quarter. Focus Partners Advisor Solutions LLC now owns 22,889 shares of the company’s stock valued at $238,000 after purchasing an additional 1,682 shares in the last quarter. Finally, ProShare Advisors LLC boosted its stake in shares of Kura Oncology by 10.0% in the 4th quarter. ProShare Advisors LLC now owns 18,572 shares of the company’s stock valued at $193,000 after buying an additional 1,692 shares during the period.

Analyst Ratings Changes

A number of research firms have recently issued reports on KURA. Sanford C. Bernstein set a $24.00 price target on shares of Kura Oncology in a research note on Monday, June 15th. Wells Fargo & Company set a $24.00 price objective on shares of Kura Oncology in a research report on Thursday, June 4th. Wall Street Zen upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 4th. Finally, Citizens Jmp restated a “market outperform” rating and set a $24.00 price target on shares of Kura Oncology in a research report on Monday, June 15th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $25.62.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.